Neuroscience is finally getting its breakthrough moment.
Real biology, returning capital, and a wave of new modalities are converging in neuroscience. But is the industry playing the wrong game by equating approval with success? “Approval” isn’t victory anymore; it’s the midpoint, and teams that celebrate too early get punished in the real world by skepticism and friction across regulators, clinicians, payers, health systems, patients, and caregivers. The provocation is blunt: most programs don’t stall because the mechanism fails. Rather they stall because the program can’t earn stakeholder confidence at scale, turning technically positive data into operationally fragile products that can’t be diagnosed, covered, delivered, or adopted.
To fix that, Lumanity lays out a commercial-first playbook built around four make-or-break hurdles: define success precisely, prove it in the right patients with proof stakeholders will believe, make the claim “travel” from trial endpoints to real-world value, and make adoption feasible (diagnosis, access, delivery capacity, workflow). The paper makes the cost of ignoring this painfully concrete: a mid-stage asset with a positive Phase II signal still hit adoption blockers when patient identification relied on unreimbursed diagnostics, endpoints were hard for clinicians to interpret, and delivery required specialized monitoring that would bottleneck access.
The takeaway is intentionally uncomfortable: the “winning” neuroscience teams won’t just discover the next mechanism, they’ll engineer the next adoptable therapy, with evidence and operations designed for scale from the start.
Download the whitepaper
"*" indicates required fields
